Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study checks if pneumonia vaccine shields HIV patients

NCT ID NCT05794191

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how effective the Prevnar 13 (PCV13) vaccine is at preventing pneumonia and related infections in adults with HIV. Researchers analyzed health records of over 350,000 people with HIV to compare those who got the vaccine with those who did not. The goal was to see if the vaccine reduces the risk of pneumococcal pneumonia and invasive disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prevnar 13 (PCV13) vaccine
What this could lead to
If the vaccine works well, it could help protect people with HIV from serious pneumonia and bloodstream infections caused by pneumococcus bacteria.
What could go wrong
This study used health records, not a controlled experiment, so results may be less reliable. The vaccine may not work as well in real-world settings or for all types of pneumonia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

350,399 people

The number who actually took part.

Started

Mar 2023

Finished

Aug 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People with HIV in a healthcare administrative database

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. HIV infection defined as at least one inpatient or ≥2 outpatient codes related to HIV at least 30 days but no more than 730 days apart 2. At least 18 years of age at the time of the first HIV-related code 3. At least six months of continuous enrollment in medical and pharmacy plans after the first HIV-related code Exclusion Criteria: 1\. Evidence of PCV13 vaccination before the first HIV-related code

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease pneumococcal infection pneumonia streptococcal pneumonia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV Infections, pneumococcal Pneumonia

Contacts and locations

Locations

  • Pfizer

    New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.